Avalyn Pharma Inc. Email Format

Biotechnology ResearchMassachusetts, United States51-200 Employees

Avalyn Pharma Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, focused on developing inhaled therapies for interstitial lung diseases, with an emphasis on pulmonary fibrosis. By delivering treatments directly to the lungs, its inhaled formulations aim to address the disease at its source and curb systemic exposure, potentially improving tolerability and lung exposure. Its lead program, AP01, is an inhaled pirfenidone being studied in Phase 2b for progressive pulmonary fibrosis, and AP02, an inhaled form of nintedanib, has completed two Phase 1 studies. Its target patients are those with serious respiratory diseases where breathlessness and disease progression are core concerns. In 2026, the company announced a poster at the EULAR 2026 conference in London, reflecting ongoing scientific engagement.

Sign up for free to view info

Company overview Employee directory